XML 76 R65.htm IDEA: XBRL DOCUMENT v3.4.0.3
SHAREHOLDERS' EQUITY (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 27, 2015
Mar. 31, 2016
Mar. 31, 2015
Increase (Decrease) in Shareholders' Equity      
Beginning Balance (in shares)   342,926,531  
Beginning Balance   $ 6,029.8 $ 5,401.7
Issuance of common stock (in shares) 7,286,432    
Issuance of common stock $ 1,450.0   1,431.9
Common shares issued under share-based compensation plans   0.8 14.5
Share-based compensation   63.5 35.0
Employee withholding taxes related to share-based awards   (7.7) (21.2)
Excess tax benefits from share-based compensation   (1.4) 17.9
Total before comprehensive income (loss)   6,085.0 6,879.8
Comprehensive (loss) income:      
Net (loss) income   (372.9) 98.5
Other comprehensive income   63.5 (411.9)
Comprehensive loss   $ (309.4) (313.4)
Ending Balance (in shares)   343,019,163  
Ending Balance   $ 5,775.6 $ 6,566.4
Common Shares      
Increase (Decrease) in Shareholders' Equity      
Beginning Balance (in shares)   342,900,000 334,400,000
Beginning Balance   $ 9,897.4 $ 8,349.2
Issuance of common stock (in shares)     7,300,000
Issuance of common stock     $ 1,431.9
Common shares issued under share-based compensation plans (in shares)   100,000 600,000
Common shares issued under share-based compensation plans   $ 8.5 $ 29.2
Total before comprehensive income (loss) (in shares)   343,000,000 342,300,000
Total before comprehensive income (loss)   $ 9,905.9 $ 9,810.3
Comprehensive (loss) income:      
Ending Balance (in shares)   343,000,000 342,300,000
Ending Balance   $ 9,905.9 $ 9,810.3
Additional Paid-In Capital      
Increase (Decrease) in Shareholders' Equity      
Beginning Balance   304.9 243.9
Common shares issued under share-based compensation plans   (7.7) (14.7)
Share-based compensation   63.5 35.0
Employee withholding taxes related to share-based awards   (7.7) (21.2)
Excess tax benefits from share-based compensation   (1.4) 17.9
Total before comprehensive income (loss)   351.6 260.9
Comprehensive (loss) income:      
Ending Balance   351.6 260.9
Accumulated Deficit      
Increase (Decrease) in Shareholders' Equity      
Beginning Balance   (2,749.7) (2,397.8)
Total before comprehensive income (loss)   (2,749.7) (2,397.8)
Comprehensive (loss) income:      
Net (loss) income   (373.7) 97.7
Ending Balance   (3,123.4) (2,300.1)
Accumulated Other Comprehensive Loss      
Increase (Decrease) in Shareholders' Equity      
Beginning Balance   (1,541.6) (915.9)
Total before comprehensive income (loss)   (1,541.6) (915.9)
Comprehensive (loss) income:      
Other comprehensive income   63.0 (411.7)
Ending Balance   (1,478.6) (1,327.6)
Valeant Pharmaceuticals International, Inc. Shareholders’ Equity      
Increase (Decrease) in Shareholders' Equity      
Beginning Balance   5,911.0 5,279.4
Issuance of common stock     1,431.9
Common shares issued under share-based compensation plans   0.8 14.5
Share-based compensation   63.5 35.0
Employee withholding taxes related to share-based awards   (7.7) (21.2)
Excess tax benefits from share-based compensation   (1.4) 17.9
Total before comprehensive income (loss)   5,966.2 6,757.5
Comprehensive (loss) income:      
Net (loss) income   (373.7) 97.7
Other comprehensive income   63.0 (411.7)
Comprehensive loss   (310.7) (314.0)
Ending Balance   5,655.5 6,443.5
Noncontrolling Interest      
Increase (Decrease) in Shareholders' Equity      
Beginning Balance   118.8 122.3
Total before comprehensive income (loss)   118.8 122.3
Comprehensive (loss) income:      
Net (loss) income   0.8 0.8
Other comprehensive income   0.5 (0.2)
Comprehensive loss   1.3 0.6
Ending Balance   $ 120.1 $ 122.9